Medresearch Inc

1. AstraZeneca Pharmaceuticals LP $482,995 6 payments
2. AstraZeneca UK Limited $415,641 9 payments
3. Eli Lilly and Company $234,303 9 payments
4. Akebia Therapeutics Inc $220,460 219 payments
5. Amgen Inc. $130,817 13 payments
6. ViiV Healthcare Company $110,135 54 payments
7. Ascendis Pharma, Inc. $109,562 59 payments
8. Retrophin, Inc. $90,293 108 payments
9. Merck Sharp & Dohme Corporation $52,544 7 payments
10. Bayer HealthCare Pharmaceuticals Inc. $50,692 39 payments

1. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $828,453 5 payments
2. A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $110,135 54 payments
3. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $101,953 2 payments
4. Akb-6548-Ci-0014 $92,891 120 payments
5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $90,230 4 payments
6. Galactic-Hf $70,177 4 payments
7. 021Fsgs16010 $67,654 88 payments
8. New InsiGHts $59,422 44 payments
9. A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $52,544 7 payments
10. Discover CKD-CVMD TA Payer and RWE Studies $47,000 5 payments

1. Other $70,984 81 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.